When all patients were evaluated regarding the positivity rate of PD-L2, the rate was higher than rates described in a few other studies evaluating the same molecule in pancreatic adenocarcinomas [17, 55]. This evidence concerns the gene PDCD1LG2 and pancreatic adenocarcinoma.